A Phase 4 interventional study of Esomeprazole 40 mg and Physical Exam in Gastroesophageal Reflux Disease, sponsored by AstraZeneca. Completed at 10 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-10-10.
Sponsored by AstraZeneca · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 67 studies testing esomeprazole in Gastroesophageal Reflux — 1 open to participants now, 1 under way, none of them phase 3. Esomeprazole · Gastroesophageal Reflux.
Among the 67 studies testing esomeprazole in Gastroesophageal Reflux, this one is the 22nd largest by enrollment of the 66 interventional ones that give a count, is one of 3 that started in 2007, is one of 28 in phase 4, and was the 45th registered.
1,215 studies on the registry are indexed under Gastroesophageal Reflux; 203 are open to participants now.
Browse Gastroesophageal Reflux studies →1 of the 67 studies testing esomeprazole in Gastroesophageal Reflux is open now, in 1 country. Recruiting first, the newest first:
Asian Institute of Gastroenterology, India · Sites in India
Ages 18–75
By country, each count listing its studies:
Esomeprazole: first FDA approval 2001 (NEXIUM), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 133 Gastroesophageal Reflux studies recruiting now, 57 (43%) set no upper age limit and 53 (40%) stop at 75 or younger; 22 take children under 18; 20 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
67 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 8 · Phase 3 17 · Phase 4 28
First in 2001; this study’s year is marked. 3 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 314 is above the median of 68 across 799 interventional studies indexed under Gastroesophageal Reflux.
Median enrollment 125 across the 66 interventional studies. Of the 58 that completed or were terminated, 13 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
43 of 67 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
89 studies in Gastroesophageal Reflux by AstraZeneca: none open now, none under way, none of them phase 3. Of 89 finished, 15 (17%) have results posted.
Among the 89 studies in Gastroesophageal Reflux by AstraZeneca, this one is the 23rd largest by enrollment of the 52 interventional ones that give a count, is one of 9 that started in 2007, is one of 21 in phase 4, and was the 55th registered.
AstraZeneca’s Gastroesophageal Reflux studies by the year they started, since 1998.
1 of the studies testing esomeprazole in Gastroesophageal Reflux that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06953986Asian Institute of Gastroenterology, IndiaA Randomized, Three-Arm Study Comparing Vonaprazan 10 mg, Vonaprazan 20 mg, and Esomeprazole 40 mg for the Healing of LA Grade B or Higher Reflux Esophagitis at 8 Weeks | 2026-11-20 |
Add it to your calendar (.ics) → With an account.
Among the 67 studies testing esomeprazole in Gastroesophageal Reflux, from their registry updates:
Among AstraZeneca’s 89 in Gastroesophageal Reflux:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess how patients with gastro-oesophageal reflux disease (heartburn) who are currently receiving treatment with a proton pump inhibitor but are still experiencing symptoms will benefit from a change in treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Esomeprazole 40 mg · Procedure: Physical Exam · Other: Quality of Life Questionnaires · Procedure: pregnancy test, if applicable
Once a day
Also known as: Nexium
every visit
every visit
as needed
Change in Frequency of Days With Heartburn From Baseline to 8 Weeks of Treatment
Reported frequency of days with heartburn at week 8 - reported frequency of days with heartburn at baseline
Time frame: At Baseline and 8 weeks
Change in Frequency of Days With Heartburn From Baseline to 4 Weeks of Treatment
Reported frequency of days with heartburn at week 4 - reported frequency of days with heartburn at baseline.
Time frame: At Baseline and 4 weeks
Change in Severity of Heartburn From Baseline to 8 Weeks of Treatment
Reported severity of heartburn at week 8 on RDQ - reported severity of heartburn at baseline on RDQ RDQ: Reflux Disease Questionnaire - by AstraZeneca LLP, 2000, values from "None" to "Severe". Four dimensions are defined for the RDQ - heartburn, regurgitation, GORD dimension and dyspepsia: stomach. Scores for each dimension are range from 0 to 5 for frequency (not present to daily) and/or severity (not present to severe).
Time frame: At Baseline and 8 weeks
Change in Severity of Heartburn From Baseline to 4 Weeks of Treatment
Reported severity of heartburn at week 4 on RDQ - reported severity of heartburn at baseline on RDQ (RDQ: Reflux Disease Questionnaire - by AstraZeneca LLP, 2000, values from "None" to "Severe". Four dimensions are defined for the RDQ - heartburn, regurgitation, GORD dimension and dyspepsia: stomach. Scores for each dimension are range from 0 to 5 for frequency (not present to daily) and/or severity (not present to severe).
Time frame: At Baseline and 4 weeks
Change in Frequency of Days With Acid Regurgitation From Baseline to 4 Weeks of Treatment.
Reported frequency of days with Acid regurgitation at week 4 - reported frequency of days with acid regurgitation at baseline. Four dimensions are defined for the Reflux Disease Questionnaire (RDQ) - heartburn, regurgitation, GORD dimension and dyspepsia: stomach. Scores for each dimension are range from 0 to 5 for frequency (not present to daily) and/or severity (not present to severe).
Time frame: At Baseline and 4 weeks.
Change in Frequency of Days With Acid Regurgitation From Baseline to 8 Weeks of Treatment.
Reported frequency of days with Acid regurgitation at week 8 - reported frequency of days with acid regurgitation at baseline. Four dimensions are defined for the Reflux Disease Questionnaire (RDQ) - heartburn, regurgitation, GORD dimension and dyspepsia: stomach. Scores for each dimension are range from 0 to 5 for frequency (not present to daily) and/or severity (not present to severe).
Time frame: At Baseline and 8 weeks.
Change in Frequency of Epigastric Pain After 4 Weeks of Treatment
Reported frequency of days with Epigastric Pain at week 4 - reported frequency of days with Epigastric Pain at baseline. Four dimensions are defined for the Reflux Disease Questionnaire (RDQ) - heartburn, regurgitation, GORD dimension and dyspepsia: stomach. Scores for each dimension are range from 0 to 5 for frequency (not present to daily) and/or severity (not present to severe).
Time frame: At Baseline and 4 weeks
Change in Frequency of Epigastric Pain After 8 Weeks of Treatment
Reported frequency of days with Epigastric Pain at week 8 - reported frequency of days with Epigastric Pain at baseline. Four dimensions are defined for the Reflux Disease Questionnaire (RDQ) - heartburn, regurgitation, GORD dimension and dyspepsia: stomach. Scores for each dimension were range from 0 to 5 for frequency (not present to daily) and severity (not present to severe).
Time frame: At Baseline and 8 weeks
Change in Severity of Epigastric Pain After 8 Weeks of Treatment
Reported severity of epigastric pain at week 8 on RDQ - reported severity of epigastric pain at baseline on RDQ (RDQ: Reflux Disease Questionnaire - by AstraZeneca LLP, 2000, values from "None" to "Severe". Four dimensions are defined for the RDQ - heartburn, regurgitation, GORD dimension and dyspepsia: stomach. Scores for each dimension are range from 0 to 5 for frequency (not present to daily) and/or severity (not present to severe).
Time frame: At Baseline and 8 weeks
Change in Severity of Epigastric Pain After 4 Weeks of Treatment
Reported severity of epigastric pain at week 4 on RDQ - reported severity of epigastric pain at baseline on RDQ (RDQ: Reflux Disease Questionnaire - by AstraZeneca LLP, 2000, values from "None" to "Severe". Four dimensions are defined for the RDQ - heartburn, regurgitation, GORD dimension and dyspepsia: stomach. Scores for each dimension are range from 0 to 5 for frequency (not present to daily) and/or severity (not present to severe).
Time frame: At Baseline and 4 weeks
Change in Severity of Acid Regurgitation After 8 Weeks of Treatment
Reported severity of acid regurgitation at week 8 on RDQ - reported severity of acid regurgitation at baseline on RDQ (RDQ: Reflux Disease Questionnaire - by AstraZeneca LLP, 2000, values from "None" to "Severe". Four dimensions are defined for the RDQ - heartburn, regurgitation, GORD dimension and dyspepsia: stomach. Scores for each dimension are range from 0 to 5 for frequency (not present to daily) and/or severity (not present to severe).
Time frame: At Baseline and 8 weeks
Change in Severity of Acid Regurgitation After 4 Weeks of Treatment
Reported severity of acid regurgitation at week 4 on RDQ - reported severity of acid regurgitation at baseline on RDQ (RDQ: Reflux Disease Questionnaire - by AstraZeneca LLP, 2000, values from "None" to "Severe". Four dimensions are defined for the RDQ - heartburn, regurgitation, GORD dimension and dyspepsia: stomach. Scores for each dimension are range from 0 to 5 for frequency (not present to daily) and/or severity (not present to severe).
Time frame: At Baseline and 4 weeks
Participants with persisting symptoms of Gastroesophageal Reflux Disease (GORD) despite previous treatment with a full dose proton pump inhibitor were enrolled across the Argentina (6 sites), Chile (3 sites) Colombia (9 sites) and Venezuela (2 sites).
| Milestone | Esomeprazole 40mg, Daily |
|---|---|
| Started | 337 |
| Completed | 317 |
| Not completed | 20 |
| Withdrew: Protocol violation | 12 |
| Withdrew: Withdrawal by subject | 5 |
| Withdrew: Lost to follow-up | 2 |
| Withdrew: Unconfirmed pregnancy | 1 |
| Milestone | Esomeprazole 40mg, Daily |
|---|---|
| Started | 317 |
| Safety analysis | 317 |
| Full analysis | 311 |
| Per protocol | 301 |
| Completed | 301 |
| Not completed | 16 |
| Withdrew: Lost to follow-up | 7 |
| Withdrew: Withdrawal by subject | 5 |
| Withdrew: Protocol violation | 4 |
Reported frequency of days with heartburn at week 8 - reported frequency of days with heartburn at baseline
| Days per week with symptoms | Esomeprazole 40mg, Daily |
|---|---|
| Change in Frequency of Days With Heartburn From Baseline to 8 Weeks of Treatment | -3.44 ± 2.35 |
Reported frequency of days with heartburn at week 4 - reported frequency of days with heartburn at baseline.
| Days per week with symptoms | Esomeprazole 40mg, Daily |
|---|---|
| Change in Frequency of Days With Heartburn From Baseline to 4 Weeks of Treatment | -3.08 ± 2.32 |
Reported severity of heartburn at week 8 on RDQ - reported severity of heartburn at baseline on RDQ RDQ: Reflux Disease Questionnaire - by AstraZeneca LLP, 2000, values from "None" to "Severe". Four dimensions are defined for the RDQ - heartburn, regurgitation, GORD dimension and dyspepsia: stomach. Scores for each dimension are range from 0 to 5 for frequency (not present to daily) and/or severity (not present to severe).
| Units of scale | Esomeprazole 40mg, Daily |
|---|---|
| Change in Severity of Heartburn From Baseline to 8 Weeks of Treatment | -1.56 ± 1.01 |
Reported severity of heartburn at week 4 on RDQ - reported severity of heartburn at baseline on RDQ (RDQ: Reflux Disease Questionnaire - by AstraZeneca LLP, 2000, values from "None" to "Severe". Four dimensions are defined for the RDQ - heartburn, regurgitation, GORD dimension and dyspepsia: stomach. Scores for each dimension are range from 0 to 5 for frequency (not present to daily) and/or severity (not present to severe).
| Units on scale | Esomeprazole 40mg, Daily |
|---|---|
| Change in Severity of Heartburn From Baseline to 4 Weeks of Treatment | -1.34 ± 1.03 |
Reported frequency of days with Acid regurgitation at week 4 - reported frequency of days with acid regurgitation at baseline. Four dimensions are defined for the Reflux Disease Questionnaire (RDQ) - heartburn, regurgitation, GORD dimension and dyspepsia: stomach. Scores for each dimension are range from 0 to 5 for frequency (not present to daily) and/or severity (not present to severe).
| Days per week with symptoms | Esomeprazole 40mg, Daily |
|---|---|
| Change in Frequency of Days With Acid Regurgitation From Baseline to 4 Weeks of Treatment. | -2.95 ± 2.42 |
Reported frequency of days with Acid regurgitation at week 8 - reported frequency of days with acid regurgitation at baseline. Four dimensions are defined for the Reflux Disease Questionnaire (RDQ) - heartburn, regurgitation, GORD dimension and dyspepsia: stomach. Scores for each dimension are range from 0 to 5 for frequency (not present to daily) and/or severity (not present to severe).
| Days per week with symptoms | Esomeprazole 40mg, Daily |
|---|---|
| Change in Frequency of Days With Acid Regurgitation From Baseline to 8 Weeks of Treatment. | -3.28 ± 2.51 |
Reported frequency of days with Epigastric Pain at week 4 - reported frequency of days with Epigastric Pain at baseline. Four dimensions are defined for the Reflux Disease Questionnaire (RDQ) - heartburn, regurgitation, GORD dimension and dyspepsia: stomach. Scores for each dimension are range from 0 to 5 for frequency (not present to daily) and/or severity (not present to severe).
| Days per week with pain | Esomeprazole 40mg, Daily |
|---|---|
| Change in Frequency of Epigastric Pain After 4 Weeks of Treatment | -2.77 ± 2.5 |
Reported frequency of days with Epigastric Pain at week 8 - reported frequency of days with Epigastric Pain at baseline. Four dimensions are defined for the Reflux Disease Questionnaire (RDQ) - heartburn, regurgitation, GORD dimension and dyspepsia: stomach. Scores for each dimension were range from 0 to 5 for frequency (not present to daily) and severity (not present to severe).
| Days per week with pain | Esomeprazole 40mg, Daily |
|---|---|
| Change in Frequency of Epigastric Pain After 8 Weeks of Treatment | -3.16 ± 2.52 |
Reported severity of epigastric pain at week 8 on RDQ - reported severity of epigastric pain at baseline on RDQ (RDQ: Reflux Disease Questionnaire - by AstraZeneca LLP, 2000, values from "None" to "Severe". Four dimensions are defined for the RDQ - heartburn, regurgitation, GORD dimension and dyspepsia: stomach. Scores for each dimension are range from 0 to 5 for frequency (not present to daily) and/or severity (not present to severe).
| Units of scale | Esomeprazole 40mg, Daily |
|---|---|
| Change in Severity of Epigastric Pain After 8 Weeks of Treatment | -1.34 ± 1.1 |
Reported severity of epigastric pain at week 4 on RDQ - reported severity of epigastric pain at baseline on RDQ (RDQ: Reflux Disease Questionnaire - by AstraZeneca LLP, 2000, values from "None" to "Severe". Four dimensions are defined for the RDQ - heartburn, regurgitation, GORD dimension and dyspepsia: stomach. Scores for each dimension are range from 0 to 5 for frequency (not present to daily) and/or severity (not present to severe).
| Units of scale | Esomeprazole 40mg, Daily |
|---|---|
| Change in Severity of Epigastric Pain After 4 Weeks of Treatment | -1.17 ± 1.1 |
Reported severity of acid regurgitation at week 8 on RDQ - reported severity of acid regurgitation at baseline on RDQ (RDQ: Reflux Disease Questionnaire - by AstraZeneca LLP, 2000, values from "None" to "Severe". Four dimensions are defined for the RDQ - heartburn, regurgitation, GORD dimension and dyspepsia: stomach. Scores for each dimension are range from 0 to 5 for frequency (not present to daily) and/or severity (not present to severe).
| Units of scale | Esomeprazole 40mg, Daily |
|---|---|
| Change in Severity of Acid Regurgitation After 8 Weeks of Treatment | -1.51 ± 1.09 |
Reported severity of acid regurgitation at week 4 on RDQ - reported severity of acid regurgitation at baseline on RDQ (RDQ: Reflux Disease Questionnaire - by AstraZeneca LLP, 2000, values from "None" to "Severe". Four dimensions are defined for the RDQ - heartburn, regurgitation, GORD dimension and dyspepsia: stomach. Scores for each dimension are range from 0 to 5 for frequency (not present to daily) and/or severity (not present to severe).
| Units of scale | Esomeprazole 40mg, Daily |
|---|---|
| Change in Severity of Acid Regurgitation After 4 Weeks of Treatment | -1.31 ± 1.06 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Esomeprazole 40mg, Daily | — | 4/317 (1.3%) | 16/317 (5%) |
| Event | Esomeprazole 40mg, Daily |
|---|---|
| Dizziness / Hypotension / TachycardiaCardiac disorders | 1/317 |
| Gastric CancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/317 |
| Vaginal haemorrhageReproductive system and breast disorders | 1/317 |
| Uterine LeiomyomaReproductive system and breast disorders | 1/317 |
| Event | Esomeprazole 40mg, Daily |
|---|---|
| HeadacheNervous system disorders | 16/317 |
| Age Continuous(Years) | Esomeprazole 40mg, Daily |
|---|---|
| Mean | 42.7 ± 14.3 |
| Sex: Female, Male(Participants) | Esomeprazole 40mg, Daily |
|---|---|
| Female | 212 |
| Male | 99 |
The record gives a start of Nov 2007, a primary completion of Oct 2008 and a completion of Oct 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2012, 4 years after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Esomeprazole